To read the article in its entirety visit http://seekingalpha.com/article/1865671
Shares of Galena have soared nearly 60 percent since November 11 when the company issued its phase I trial results of its Folate Binding Protein (FBP) vaccine for endometrial and ovarian cancer. The rally accrued additional investor interest and was further fueled by analyst action.
Oppenheimer Monday initiated an Outperform rating on Galena’s stock and set a 12-18-month price target of $6.
“The coverage by Oppenheimer came as positive news, as it further strengthens the positive sentiment surrounding the company, which was translated into the share prices yesterday. The pipeline candidates of Galena are indeed promising, having expected blockbuster potential,” the article states.
Referencing Galena’s marketing of Abstral®, for which the company reported $1.2 million in sales before the official product launch, Stock Whisper writes, “Hence, it is right to say that Abstral in the coming quarters may prove to be a major value creator for the company and help pave the way towards a profitable company.”
The article also discusses NeuVax, the company’s potential blockbuster drug for breast cancer treatment and its opportunity in the healthcare market.
“…If we take the same cost for NeuVax, the potential annual sales amount to a stellar $8.4 billion. Even if Galena succeeds in capturing only 10% of the market, the annual sales for the drug would be 840 million. Thus this provides a massive potential for the company, when and if it’s approved.”
In conclusion, the article dubs Galena “a fair investment, with major long term potential. The current price is a profitable entry point for long term investors as the share prices are bound to take off and will bring in huge gains.”
For more information, visit www.galenabiopharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
